[Contribution of transgenesis models in discovery of new pharmacological targets in heart failure: aldosterone receptor as an example].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Latouche C;Latouche C; Jaisser F
  • Source:
    Therapie [Therapie] 2009 Mar-Apr; Vol. 64 (2), pp. 81-6. Date of Electronic Publication: 2009 Aug 11.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    French
  • Additional Information
    • Transliterated Title:
      Apport des modèles transgéniques dans la recherche de nouvelles cibles pharmacologiques dans l'insuffisance cardiaque: l'exemple du récepteur de l'aldostérone.
    • Source:
      Publisher: Elsevier Masson Country of Publication: France NLM ID: 0420544 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0040-5957 (Print) Linking ISSN: 00405957 NLM ISO Abbreviation: Therapie Subsets: MEDLINE
    • Publication Information:
      Publication: 2016- : Paris : Elsevier Masson
      Original Publication: Paris : Doin
    • Subject Terms:
      Animals, Genetically Modified/*physiology ; Heart Failure/*drug therapy ; Heart Failure/*genetics ; Receptors, Mineralocorticoid/*drug effects ; Receptors, Mineralocorticoid/*genetics; Aldosterone/physiology ; Animals ; Humans ; Receptors, Mineralocorticoid/physiology
    • Abstract:
      Heart failure is a complex illness with multiple etiologies. Therapeutic targets are numerous such as neurohormonal blockade (adrenergic and renin-angiotensin-aldosterone systems). Progress in therapeutic strategy and efficacy could be expected from individual treatment taking into account biomarkers so called "theragnostic". Animal models, classical or genetically modified, have conducted to a better identification and validation of signal pathways in heart failure. Furthermore these models allow testing of new hypothesis and therapeutic approaches, although cardiovascular physiology and physiopathological patterns are far different in animals than in humans (haemodynamic conditions, kinetic development of the illness, old age, ...). Last, identification of putative theragnostic biomarkers is easier (i.e. free access, homogeneity of experimental cohorts). Genetically modified models by classical additive transgenesis techniques or gene targeting have an important role in discovery of new pharmacological targets in heart failure. Study of the role of aldosterone and of its receptor (mineralocorticosteroid receptor) in the physiopathology of heart failure and as a new therapeutic target will be used as an Ariane's clew to demonstrate that translational bidirectional research (from integrated experimental model to bedside and from clinical results to bench) has allowed from these 15 last years: i) to propose changes in therapeutic strategies and ii) to stimulate research of new targets and new mineralocorticosteroid receptor antagonists.
    • Number of References:
      35
    • Accession Number:
      0 (Receptors, Mineralocorticoid)
      4964P6T9RB (Aldosterone)
    • Publication Date:
      Date Created: 20090812 Date Completed: 20091005 Latest Revision: 20131121
    • Publication Date:
      20221213
    • Accession Number:
      10.2515/therapie/2009024
    • Accession Number:
      19664400